Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 461 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Immune Globulin Intravenous (Human) Clear all
Completed Phase 1 Interventional

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

NCT04147819
View directory record Official record
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT02788188
View directory record Official record
Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
SAB-301, Normal (9%) Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881, HyQvia, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

NCT02648490
View directory record Official record
Conditions
Solid Tumour
Interventions
HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
Drug
Lead sponsor
Henlix, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629
View directory record Official record
Conditions
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
30 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Withdrawn Phase 2 Interventional

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

NCT03574649
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 10, 2026, 2:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

NCT05141149
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PBP1510 (400mg/16mL), Gemcitabine (1000 mg/m^2)
Drug
Lead sponsor
Prestige Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT01121185
View directory record Official record
Conditions
HCV Infection, Liver Transplantation
Interventions
MBL-HCV1, 0.9% Sodium chloride Placebo
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

NCT00354419
View directory record Official record
Conditions
Aplastic Anemia
Interventions
total-body irradiation, cyclophosphamide, anti-thymocyte globulin, cyclosporine, umbilical cord blood transplantation, mycophenolate mofetil, bone marrow aspiration, DNA analysis, filgrastim
Radiation · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

NCT04590430
View directory record Official record
Conditions
Healthy
Interventions
HFB30132A, Placebo
Drug · Other
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

NCT03082209
View directory record Official record
Conditions
Advanced Solid Tumors, Cancer, Hematologic Malignancies
Interventions
ABBV-621, Venetoclax, Bevacizumab, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
New Haven, Connecticut • Chicago, Illinois • Harvey, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Interventions
Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions
Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

NCT04374877
View directory record Official record
Conditions
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions
CHS-388, Pembrolizumab, Toripalimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions
ALE.P03
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312
View directory record Official record
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Orange, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 10, 2026, 2:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Yellow Fever Virus Vaccine and Immune Globulin Study

NCT00254826
View directory record Official record
Conditions
Viremia
Interventions
YF-VAX® plus saline, 17D YF Vaccine plus Ig,
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

NCT05293912
View directory record Official record
Conditions
Hematological Malignancy, Lymphoma
Interventions
SG2501
Drug
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
8
States / cities
Atlanta, Georgia • Hackensack, New Jersey • Hawthorne, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 10, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03119428
View directory record Official record
Conditions
Locally Advanced Cancer, Metastatic Cancer
Interventions
OMP-313M32, Nivolumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • Durham, North Carolina • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 1 Interventional

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions
XmAb541
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
15 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter's Transformation
Interventions
Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
Drug
Lead sponsor
Christine Ryan
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 10, 2026, 2:09 PM EDT